Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Micreos Human Health.

    Client Virtual Booth

    MICREOS HUMAN HEALTH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Micreos Human Health
    Netherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    A. van Leeuwenhoeklaan 9 Gebouw SR 3721 MA Bilthoven
    Telephone
    Telephone
    +31 (0) 88 800 7100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.micreos.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Investigational Study Provides Evidence that Recombinant Endolysin XZ.700* Is a Promising Novel Non-Antibiotic Treatment Strategy Aimed at Controlling S...

    Details:

    MEndoC (XZ.700) is a world-class endolysin platform, as a topical treatment of the inflammatory skin symptoms associated with CTCL. Studies have shown that aggressive antibiotic treatment inhibits proliferation of malignant T-cells and disease activity.


    Lead Product(s): XZ.700

    Therapeutic Area: Infections and Infectious Diseases Product Name: MEndoC

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 07, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Micreos’ Alternative to Antibiotics Secures Next €25 Million

    Details:

    Proceeds includes the clinical development of XZ.700 for endolysins against staphylococci (including MRSA) for Bloodstream Infections, Atopic Dermatitis, Diabetic Foot Ulcers and Cutaneous T-cell Lymphoma, a type of skin cancer associated with presence of S. aureus bacteria.


    Lead Product(s): XZ.700

    Therapeutic Area: Dermatology Product Name: XZ.700

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Undisclosed

    Deal Size: $24.5 million Upfront Cash: Undisclosed

    Deal Type: Financing October 25, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Micreos Secures €32 Million for Its Endolysin-Based Platform as Sustainable Alternative to Antibiotics

    Details:

    This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.


    Lead Product(s): XZ.700

    Therapeutic Area: Dermatology Product Name: XZ.700

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Undisclosed

    Deal Size: $37.1 million Upfront Cash: Undisclosed

    Deal Type: Funding September 30, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Micreos Initiates Clinical Trial to Evaluate World’s First Endolysin-Drug as a Therapy for Atopic Dermatitis

    Details:

    Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.


    Lead Product(s): XZ.700

    Therapeutic Area: Dermatology Product Name: XZ.700

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 22, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search